✦ LIBER ✦

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer

✍ Scribed by Ivana Sestak, Michelle Harvie, Anthony Howell, John F. Forbes, Mitch Dowsett, Jack Cuzick

Book ID: 113062495
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 187 KB
Volume: 134
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-012-2085-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacoeconomic aspects of adjuvant ear

Pharmacoeconomic aspects of adjuvant early breast cancer treatment in postmenopausal women with anastrozole or tamoxifen: a Slovenian perspective

✍ P Piskur; M Sonc; T Cufer; S Borstnar; A Mrhar 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 180 KB

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 150 KB

Pharmacoeconomic analysis of adjuvant th

Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer

✍ Juan Miguel Gil; Carlos Rubio-Terrés; Almudena del Castillo; Paloma González; Fe 📂 Article 📅 2006 🏛 Springer Milan 🌐 Spanish ⚖ 827 KB

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d

PCN6 A COST-EFFECTIVENESS ANALYSIS OF AD

PCN6 A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH EXEMESTANE, ANASTROZOLE, LETROZOLE OR TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLYSTAGE BREAST CANCER IN MEXICO

✍ J Mould-Quevedo; J Tapia-Valencia; G Davila-Loaiza 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Anastrozole is safer and may be more eff

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer: Abstracted from: Baum M, Buzdar A, Cuzick J, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003;98:1802–10

✍ Hetty Carraway; Antonio C. Wolff 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB